Financial Performance - For the first quarter of 2025, the company reported a revenue of RMB 1,541,215,508.36, representing a year-on-year increase of 10.10%[9] - The net profit attributable to shareholders was RMB 326,607,817.72, reflecting a growth of 15.83% compared to the same period last year[9] - The net profit after deducting non-recurring gains and losses was RMB 305,112,828.34, which is a 20.14% increase year-on-year[9] - Basic and diluted earnings per share increased to RMB 0.89, up 17.11% from RMB 0.76 in the previous year[9] - Operating profit amounted to RMB 358,637,868.11, reflecting a growth of 21.7% from RMB 294,688,697.62 in the prior period[26] - Net profit for the period was RMB 324,571,255.22, up 16.1% from RMB 279,529,194.27 year-over-year[27] - The total comprehensive income for the current period was RMB 325,416,000, up from RMB 279,822,000 in the previous period[35] - Adjusted net profit attributable to shareholders for Q1 2025 was RMB 330,393,000, compared to RMB 267,120,000 in Q1 2024, indicating a growth of approximately 23.7%[42] - The adjusted net profit margin for Q1 2025 improved to 21.44%, up from 19.08% in Q1 2024[42] Assets and Liabilities - Total assets at the end of the reporting period were RMB 19,447,176,497.82, a 0.82% increase from the previous year-end[9] - The equity attributable to shareholders rose to RMB 17,179,977,026.38, marking a 1.99% increase compared to the previous year-end[9] - Total liabilities decreased to RMB 2,252,047,978.35 from RMB 2,425,984,466.06, representing a reduction of 7.1%[24] - Current assets totaled RMB 11,151,587,441.54, slightly up from RMB 11,050,175,723.88 at the start of the period, indicating a 0.9% increase[22] - The company's total assets less current liabilities amounted to RMB 17,888,660,000, an increase from RMB 17,579,211,000 in the previous year[38] Cash Flow - The company's cash flow from operating activities showed a net decrease of 8.42%, amounting to RMB 449,341,852.23[9] - Operating cash flow for the current period was RMB 449,341,852.23, a decrease of 8.4% from RMB 490,666,474.36 in the previous period[30] - The net increase in cash and cash equivalents for the current period was RMB 1,307,854,379.23, significantly higher than RMB 3,058,460.18 in the previous period[31] - The company reported a net cash inflow from investing activities of RMB 843,986,000 in Q1 2025, contrasting with a net cash outflow of RMB 284,603,000 in Q1 2024[41] - Cash and bank balances at the end of the period were RMB 6,801,984,000, an increase from RMB 5,789,408,000 in the previous year[37] Investments and Expenses - Trading financial assets decreased by 50.35% to ¥764,449,856.30 due to a reduction in low-risk bank deposits[14] - Financial expenses decreased by 42.61% to ¥(44,939,637.49) primarily due to a decrease in exchange gains from currency fluctuations[14] - Investment income cash receipts increased by 51.21% to ¥50,475,852.08 due to higher fixed-term interest income[14] - Cash paid for investments decreased by 40.02% to ¥1,992,870,856.24 mainly due to a reduction in purchases of low-risk bank wealth management products[14] - The company's depreciation expense for property, plant, and equipment was RMB 114,895,000 in Q1 2025, compared to RMB 103,908,000 in Q1 2024, reflecting an increase of approximately 10.5%[40] Shareholder Information - The total number of common shareholders at the end of the reporting period was 43,585[15] - ASYMCHEM LABORATORIES, INCORPORATED holds 31.93% of shares, totaling 115,133,168 shares[16] - The top ten shareholders include various entities, with the largest being ASYMCHEM LABORATORIES, INCORPORATED[16] - The company has not reported any significant changes in the participation of major shareholders in margin financing activities[20] Business Development - The company continues to implement cost reduction and efficiency enhancement measures to support ongoing business growth[10] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[26] - The company’s small molecule CDMO business maintained stable development with a gross margin of 45.17%[10] - Emerging businesses, particularly in peptides, oligonucleotides, and ADCs, achieved over 80% revenue growth year-on-year with a gross margin of 33.05%[10]
凯莱英(06821) - 2025 Q1 - 季度业绩